Wednesday, 16th October 2019
Logo

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

Multiyear alliance underpins the Novartis commitment to leverage data & artificial intelligence (AI) to transform how medicines are discovered, developed and commercialized.

Novartis has announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft Corp. as its strategic AI and data-science partner for this effort. The new lab aims to significantly bolster Novartis AI capabilities from research through commercialization and help accelerate the discovery and development of transformative medicines for patients worldwide.

As part of the strategic collaboration announced, Novartis and Microsoft have committed to a multi-year research and development effort. This strategic alliance will focus on two core objectives:

  • AI Empowerment. The lab will aim to bring the power of AI to the desktop of every Novartis associate. By bringing together vast amounts of Novartis datasets with Microsoft’s advanced AI solutions, the lab will aim to create new AI models and applications that can augment our associates’ capabilities to take on the next wave of challenges in medicine.
  • AI Exploration. The lab will use the power of AI to tackle some of the hardest computational challenges within the life sciences, starting with generative chemistry, image segmentation & analysis for smart and personalized delivery of therapies, and optimization of cell and gene therapies at scale.

Microsoft and Novartis will also collaborate to develop and apply next-generation AI platforms and processes that support future programs across these two focus areas. The overall investment will include project funding, subject-matter experts, technology, and tools.

Vas Narasimhan, CEO of Novartis, said, “As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend lives. Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world.”

Microsoft CEO, Satya Nadella, added, “Our strategic alliance will combine Novartis’ life sciences expertise with the power of Azure and Microsoft AI. Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs.”

Global research highlights how AI is changing the relationship between people and technology at work...
Majority of organisations neglect due diligence during the artificial intelligence development phase...
Amherst College, Howard University, and Suffolk University among the latest to adopt the SnapLogic p...
Fujitsu Laboratories, Ltd. and Fujitsu Laboratories of America, Inc. have developed an AI facial exp...
Only half of UK IT firms plan to increase investment in AI over the next 5 years, compared to over 7...
Organisations using AI are outperforming competitors by 11.5 per cent, according to research by Micr...
A global first, new pilot utilizes IPsoft’s industry-leading Amelia technology to pursue a strategic...
This second agreement is aimed at developing and marketing a software solution to help radiologists...